Skip to content
Sakar Healthcare logo

Sakar Healthcare

SAKAR NSE
₹989.00 58.70 (6.31%)
Market Cap
₹2,201 Cr
P/E
60.97

Sakar Healthcare (SAKAR) share price was ₹989.00 at the 28 Oct 2026 close; market capitalisation ₹2,201 Cr; P/E (TTM) 60.97; sector Healthcare. The share price rose 179.1% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 38.5% year on year to ₹73.0 Cr and net profit was ₹10 Cr, against ₹5 Cr a year earlier (compared with Jun 2025). Promoters held 51.70% of Sakar Healthcare in Sep 2026, down 0.82 percentage points from Jun 2026. Its Tapetide Score is 49/100 (Average) as of 28 Oct 2026.

Close 28 Oct 2026 ₹989.00 +634.60 +179.06% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹2,201 Cr
P/E (TTM)
60.97
EBITDA
₹71.20 Cr
Return on Equity
9.4%
Debt to Equity
0.22
Book Value
₹155.50
EPS (TTM)
₹16.22
52W High
₹1,229.85
52W Low
₹352.05

Price-based figures as of 28 Oct 2026, 15:31 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Sakar Healthcare (this company)
₹989.0060.972,201 Cr6.360.00%9.40%12.82%304 Cr36 Cr
Median 8 companies₹1,561.5547.921,17,574 Cr5.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
49 Average
Overall score
Data confidence 100/100
surveillance:ASM1insider_selling

Category scores

Quality Good 62
Returns, margins, earnings quality 22%
Valuation Poor 29
Cheap vs sector & own history 24%
Growth Strong 99
Sales & profit trajectory 9%
Financial Health Good 64
Solvency, leverage, coverage 9%
Momentum Strong 82
Trend strength, vol-adjusted 12%
Ownership Good 62
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • Company's median sales growth is 18.0% of last 10 years

Weaknesses

4
  • Stock is trading at 6.41 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -0.82%
  • Company has a low return on equity of 7.49% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
3
Neutral
6
Bullish
0

Overall

BearishNeutralBullish

Bullish

Bearish
5
Neutral
6
Bullish
8

Moving Averages

BearishNeutralBullish

Bullish

Bearish
2
Neutral
0
Bullish
8
Analyst Rating
Based on 1 analysts
BUY SHARE100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

Updated 28 Oct 2026

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

Revenue Growth
41.98% higher than 3Y

change over 1 year

Net Income Growth
74.29% higher than 3Y

change over 1 year

Cash Flow Change
44.75%

change over 1 year

EBITDA Margin Change
-1.72%

change over 1 year Operating margin 29% · Jun 2026

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹96.7 Cr +35.8% vs FY26
Reported High Mean Low

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
39
34
37
43
41
43
43
50
53
58
70
71
73
Expenses
30
25
28
32
30
31
32
35
40
46
52
45
52
Operating Profit
9
9
9
11
11
12
12
16
13
11
19
26
21
OPM %
23%
27%
24%
25%
26%
27%
27%
31%
24%
20%
26%
37%
29%
Other Income
2
1
0
1
0
0
0
0
0
1
1
0
2
Interest
2
2
2
2
1
2
1
4
2
2
2
2
2
Depreciation
5
4
4
5
5
5
5
5
6
6
6
6
7
PBT
4
4
3
5
5
5
5
6
5
5
11
18
15
Tax %
28%
13%
31%
35%
49%
6%
17%
8%
13%
15%
6%
39%
29%
Net Profit
3
4
2
3
2
5
5
6
5
5
10
11
10
EPS (₹)
1.49
1.7
0.95
1.43
1.11
2.21
2.06
2.62
2.1
2.04
4.61
4.95
4.62
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
35
41
44
53
68
83
95
128
133
153
178
251
272
Expenses
27
33
34
40
51
63
72
99
100
115
128
182
195
Operating Profit
8
8
10
13
17
20
23
29
33
38
50
69
77
OPM %
22%
20%
23%
24%
25%
24%
24%
23%
25%
25%
28%
27%
28%
Other Income
0
0
1
0
1
2
1
2
5
3
1
2
3
Interest
3
3
3
3
2
2
2
3
6
8
9
8
7
Depreciation
2
3
3
4
6
7
8
10
15
18
21
24
25
PBT
2
3
5
6
9
12
13
19
17
16
22
40
49
Tax %
24%
22%
30%
38%
28%
21%
19%
20%
24%
27%
19%
23%
—
Net Profit
2
2
3
4
7
10
11
15
13
12
18
30
36
EPS (₹)
2.3
2.78
3.08
3.12
4.47
6.43
6.84
8.9
6.7
5.37
7.97
13.7
16.22
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
11
12
15
15
16
17
19
22
22
22
Reserves
7
11
25
39
57
66
83
110
154
241
264
302
Borrowings
25
22
24
11
11
17
43
93
119
79
86
71
Other Liabilities
11
10
11
18
15
17
37
47
44
47
43
86
Total Liabilities
50
51
71
81
97
115
178
268
336
389
415
481
Fixed Assets
36
37
49
53
64
66
69
205
267
314
309
326
CWIP
0
0
0
0
9
13
49
1
6
0
17
4
Investments
0
0
0
0
0
0
0
7
3
0
0
0
Other Assets
14
14
22
28
25
36
60
55
60
74
90
151
Total Assets
50
51
71
81
97
115
178
268
336
389
415
481
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
9
2
5
16
19
15
36
33
24
34
49
Investing
-1
-4
-14
-8
-25
-22
-47
-90
-74
-52
-31
-28
Financing
-3
-6
13
-13
9
3
32
55
41
27
-3
-21
Net Cash Flow
1
-1
0
-16
0
0
0
0
0
0
0
0
Free Cash Flow
4
5
-13
-4
-9
-4
-32
-62
-49
-35
2
21
CFO/EBITDA
60
117
30
51
104
110
67
121
113
72
73
77
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
21
26
44
74
51
36
48
40
60
50
63
73
Inventory Days
142
107
114
51
70
92
112
69
76
121
193
207
Days Payable
20
66
51
57
41
46
141
149
129
120
93
153
Cash Conversion Cycle
143
67
107
68
80
83
19
-39
7
51
163
127
Working Capital Days
27
10
67
98
31
31
2
-11
-6
29
52
45
ROCE %
14%
14%
15%
14%
16%
16%
13%
12%
9%
7%
9%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sakar Healthcare insights

65 extracted metrics + investor summaries across FY15–FY27.

Shareholding Pattern

Others3.63%Promot.51.70%DIIs11.92%FIIs12.34%Public20.42%As ofSep 2026

Documents

Frequently Asked Questions about Sakar Healthcare

What does Sakar Healthcare Ltd do?
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
Where is Sakar Healthcare Ltd (SAKAR) listed?
Sakar Healthcare Ltd trades as SAKAR on the NSE.
Which sector does Sakar Healthcare Ltd belong to?
Sakar Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Sakar Healthcare Ltd?
Sakar Healthcare Ltd has a market capitalisation of ₹2,201 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Sakar Healthcare Ltd?
Sakar Healthcare Ltd trades at a PE ratio of 60.97 as of 28 Oct 2026, on earnings per share of ₹16.22, against a book value of ₹155.5 per share.
What is the 52-week high and low of Sakar Healthcare Ltd?
Over the last 52 weeks Sakar Healthcare Ltd has traded between ₹352.05 and ₹1,229.85 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Sakar Healthcare Ltd?
Sakar Healthcare Ltd reported a return on equity of 9.40%. Its debt-to-equity ratio is 0.22.

Company Information

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

Website sakarhealthcare.com
Listed 2019-04-11
Face Value ₹ 10
Shares Outstanding 2,22,49,910

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SAKAR.md for Sakar Healthcare Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month